The goal of this clinical trial is to determine whether treatment with indapamide can slow the rate of progression in patients with progressive forms of multiple sclerosis (MS). The main question it aims to answer is whether this treatment can reduce the speed at which the walking speed of patients with progressive MS (PMS) worsens. Participants will take an indapamide tablet once daily for 12 months. During this time, among others, their walking speed will be assessed several times.
Written informed consent obtained
Aged between 18 and 65 years
Diagnosed with PPMS or SPMS, according to current diagnostic criteria
Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive.
Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2
Individuals with a blood pressure below 110 mmHg systolic or 70 mmHg diastolic
Individuals with significant hepatic impairment (pre-existing or developing during the trial)
Individuals with clinically significant abnormal screening labs
Eva M.M. Strijbis
Lead sponsor
Amsterdam University Medical Center
Sponsor institution